ConvaTec Regulatory News (CTEC)

1 August 2024

Convatec Group Plc("Convatec" or "the Company")

Convatec Director Declaration

The Company announces that effective today Brian May, a non-executive director of the Company, serves as a director of Ferguson Enterprises Inc., which is the new ultimate parent company of the Ferguson plc group, in place of Ferguson plc, pursuant to a corporate reorganisation. Ferguson Enterprises Inc. is a publicly quoted company with a primary listing on the New York Stock Exchange (NYSE: FERG) effective from 1 August 2024 and a secondary listing on the equity shares (international commercial companies secondary listing) segment of the Official List of the Financial Conduct Authority and is admitted to trading on the London Stock Exchange (LSE:FERG). In connection with the reorganisation, Brian May ceased to be a non-executive director of Ferguson plc.

This announcement is made in accordance with UK Listing Rule 6.4.9R. 

Enquiries 

James Kerton, EVP, General Counsel & Company Secretary, Convatec 

James.kerton@convatec.com

+44(0)7827 036059

Convatec Group Plc's LEI code is 213800LS272L4FIDOH92 

About Convatec 

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in advanced wound care, ostomy care, continence and critical care, and infusion care. With around 10,000 colleagues, we provide our products and services in almost 100 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Group revenues in 2023 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more about Convatec, please visit http://www.convatecgroup.com